Dose-Dense Chemotherapy Regimen for Breast Cancer Associated with Significant Decline in Ovarian Reserve.
| Autor: | Chamani, Isaac J., Gannon, Alexandra, Connell, Phillip T., Bisen, Ajit, Kovanci, Ertug, Sangi-Haghpeykar, Haleh, Woodard, Terri, McKenzie, Laurie J. |
|---|---|
| Předmět: |
BREAST tumor diagnosis
SEX hormones BREAST tumors RETROSPECTIVE studies DESCRIPTIVE statistics DOSE-effect relationship in pharmacology CANCER chemotherapy LONGITUDINAL method PRE-tests & post-tests MEDICAL records ACQUISITION of data DOXORUBICIN OVARIAN reserve WOMEN'S health PACLITAXEL CYCLOPHOSPHAMIDE |
| Zdroj: | Journal of Adolescent & Young Adult Oncology; Jun2024, Vol. 13 Issue 3, p465-468, 4p |
| Abstrakt: | Purpose: To determine the impact of dose-dense chemotherapy administration on ovarian reserve in women undergoing treatment for breast cancer. Patients and Methods: We conducted a retrospective cohort study of reproductive age women who underwent dose-dense chemotherapy regimens with doxorubicin hydrochloride and cyclophosphamide with or without paclitaxel for a new diagnosis of breast cancer. We compared pre- and post-treatment serum antimullerian hormone (AMH) levels and assessed changes in AMH over time. Results: Fifty-seven patients met inclusion criteria. Median pre-treatment AMH was 2.9 ng/mL, whereas post-treatment AMH was 0.1 ng/mL, demonstrating a dramatic reduction in AMH levels after treatment with a dose-dense regimen. This change was independent of age and was sustained over 12 months from treatment completion. Conclusions: Dose-dense chemotherapy regimens for breast cancer lead to marked and sustained decreases in AMH irrespective of patient age. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|